Search clinical trials for: BIBF 1120

Total 165 results

Hoosier Cancer Research Network
Boehringer Ingelheim

Terminated

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Ovarian Cancer

United States
PharmaMar

Completed

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL)

Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

Healthy
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Genetic Epidemiology of Coronary Heart Disease Risk in Women Twins

Heart Diseases | Cardiovascular Diseases | Coronary Disease
Kumamoto University

Completed

Impaired Peripheral Endothelial Function and In-stent Restenosis

Coronary Artery Disease

Japan
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Recurrent Pleural Malignant Mesothelioma | Stage IV Pleural Mesothelioma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim

Completed

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

Lung Cancer | Lung Metastases

United States
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
National Taiwan University Hospital

Unknown

BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma

Urothelial Carcinoma

Taiwan
Ain Shams University

Recruiting

Osseodensification Versus Osteotome Internal Sinus Lifting in Delayed Implant Placement

Maxillary Sinus Floor Augmentation

Egypt
University Hospital, Grenoble

Terminated

Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE) (PROPAGE)

Lung Infection

France
Alhasan Mujtaba Al-Mudhaffer
Ministry of Health, Iraq; University of Basrah

Completed

COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients

Depression | Covid19 | Anxiety

Iraq
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive...

Completed

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
Boehringer Ingelheim

Completed

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
Ulrik Lassen
University of Copenhagen; Boehringer Ingelheim

Completed

BIBF 1120 in Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma

Denmark
Boehringer Ingelheim

Completed

Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Terminated

Nintedanib (BIBF 1120) in Mesothelioma

Mesothelioma

United States, Spain, Canada, United Kingdom, Belgium, Czechia, Sweden, Australia, Germany, Italy, Japan, Russian Federation, Israel, Poland, France, Netherlands, Austria, Mexico, Portugal, Egypt, Argentina, Croatia, Chile, Denmark, Norway and more
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Northwestern University
National Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...

Active, not recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem Duplication

United States
Boehringer Ingelheim

Terminated

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Ovarian Neoplasms

Japan
University College, London
Boehringer Ingelheim

Completed

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (METRO-BIBF)

Ovarian Cancer | Fallopian Tube Cancer

United Kingdom
Boehringer Ingelheim

Completed

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

Spain
Boehringer Ingelheim

Completed

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

Healthy
Patrick Y. Wen, MD
Massachusetts General Hospital; Boehringer Ingelheim; The Cleveland Clinic; Wake... and other collaborators

Completed

BIBF 1120 for Recurrent High-Grade Gliomas

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Germans Trias i Pujol Hospital
Fundació Recerca Institut Germans Trias i Pujol; Istituto Superiore di Sanità

Active, not recruiting

Abuse Potential and Human Pharmacology of Methylone (METI/FIS/1)

Healthy Subjects | Substance Use

Spain
Boehringer Ingelheim

Completed

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Carcinoma, Renal Cell

United Kingdom, Poland, Hungary, Romania, Ukraine
Boehringer Ingelheim

Completed

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Colorectal Neoplasms

Belgium, France, Germany, Italy, Spain
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV... and other conditions

United States
Centro Nacional de Investigaciones Oncologicas...
M.D. Anderson Cancer Center; Hospital Universitari de Bellvitge; Grupo Espanol... and other collaborators

Completed

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Breast Cancer

Spain
AHS Cancer Control Alberta
Boehringer Ingelheim; Cross Cancer Institute

Withdrawn

A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

Small Cell Lung Cancer | Platinum-sensitive

Canada
University of Cologne
Boehringer Ingelheim

Completed

BIBF 1120 and RAD001 in Solid Tumors - Phase I (BARIS)

Solid Tumors

Germany
AA Secord
Boehringer Ingelheim

Completed

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
JI-YOUN HAN
National Cancer Center, Korea

Completed

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Recurrent

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Neoplasms

United States
Boehringer Ingelheim

Completed

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Tumors
Boehringer Ingelheim

Completed

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Neoplasms

France, Germany
Boehringer Ingelheim

Completed

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Tumors
Boehringer Ingelheim

Completed

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Malignant Solid Tumour

Germany
Boehringer Ingelheim

Completed

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

Idiopathic Pulmonary Fibrosis

Japan
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

Healthy
M.D. Anderson Cancer Center
Boehringer Ingelheim

Terminated

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Breast Cancer

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Pulmonary Fibrosis

United States, Canada, Chile, China, Finland, France, Germany, Greece, India, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, Spain, Turkey
Boehringer Ingelheim

Completed

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Neoplasms

Italy

Search clinical trials for: BIBF 1120

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations